James M. Brophy, MD, PhD; Patrick Belisle, MSc; Lawrence Joseph, PhD
Grant Support: Dr. Brophy was supported by Les Fonds de la Recherche en Santé du Québec and Dr. Joseph by the Canadian Institutes of Health Research.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: James Brophy, MD, PhD, Division of Epidemiology, McGill University Health Center (MUHC), Royal Victoria Hospital, 687 Pine Avenue West, Room 4.12, Montreal, Quebec H3A 1A1, Canada; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Brophy: Division of Epidemiology, McGill University Health Center (MUHC), Royal Victoria Hospital, 687 Pine Avenue West, Room 4.12, Montreal, Quebec H3A 1A1, Canada.
Mr. Belisle and Dr. Joseph: Division of Clinical Epidemiology, Montreal General Hospital, McGill University, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.
Author Contributions: Conception and design: J.M. Brophy, L. Joseph.
Analysis and interpretation of the data: J.M. Brophy, P. Belisle, L. Joseph.
Drafting of the article: J.M. Brophy, L. Joseph.
Critical revision of the article for important intellectual content: J.M. Brophy, P. Belisle, L. Joseph.
Final approval of the article: J.M. Brophy, P. Belisle, L. Joseph.
Statistical expertise: J.M. Brophy, P. Belisle, L. Joseph.
Obtaining of funding: J.M. Brophy.
Administrative, technical, or logistic support: J.M. Brophy
Collection and assembly of the data: J.M. Brophy, L. Joseph.
Brophy J., Belisle P., Joseph L.; Evidence for Use of Coronary Stents: A Hierarchical Bayesian Meta-Analysis. Ann Intern Med. 2003;138:777-786. doi: 10.7326/0003-4819-138-10-200305200-00005
Download citation file:
Published: Ann Intern Med. 2003;138(10):777-786.
Percutaneous transluminal coronary angioplasty (PTCA) is a common intervention that is used primarily to reduce the symptoms of angina pectoris; it has no discernible benefit for reducing rate of myocardial infarction or death when compared with other treatments (1). An important limitation of PTCA has been the occurrence of restenosis. Coronary stenting is a percutaneous technique involving the intraluminal introduction of metal scaffolding. Coronary stenting was introduced in 1989 to treat the acute complications of PTCA (2) but is now routinely used for most angioplasties. The elective stent era began with the publication in 1994 of two randomized clinical trials showing a reduced rate of restenosis with coronary stenting compared with ordinary PTCA (3, 4). Subsequently, the use of stents has increased exponentially; some consensus panels endorsed this clinical enthusiasm for coronary stenting even before a large body of high-quality evidence was available (5).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Coronary Heart Disease, Percutaneous Coronary Intervention.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only